Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat |
| |
Authors: | Ishigaki Noriko Yamamoto Naoki Jin Haiyan Uchida Kouichi Terai Shuji Sakaida Isao |
| |
Institution: | Department of Gastroenterology and Hepatology, Yamaguchi University, Graduated School of Medicine, Minami-Kogushi 1-1-1 Ube, Yamaguchi 755-8505, Japan |
| |
Abstract: | The atrial natriuretic peptide (ANP) are used as the acute heart failure treatment in clinical and reported the suppression of fibrosis in the heart, lung recently. The aim of this study was to analyze the suppressive effect of liver fibrosis about ANP. In vitro, rat hepatic stellate cell line (HSC-T6) were treated with ANP. In vivo, Wister rats were injected with dimethylnitrosamine (DMN) twice a week via intra-peritoneal for 4 weeks. ANP group was given by continuance intravenous dosage system used 24 h infusion pump for 3 weeks after 1 week of DMN administration. In vitro, ANP suppressed α-SMA expression and was inhibited the growth of HSC, and reduced the expression of type 1 procollagen, TIMP-1, -2 expression. In vivo, The ANP group showed lower serum AST, ALT, HA level. Liver fibrosis was suppressed by ANP. ANP also decreased gene expression of type 1 procollagen, TIMP-1, -2 and α-SMA, TGF-β1 expression. Our results showed that continuous ANP infusion has the specific capacity of inhibiting HSC activation and protecting hepatocytes and the useful capacity to suppress the liver fibrosis. |
| |
Keywords: | DMN diethylnitrosamine ANP atrial natriuretic peptide |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|